Data / Form D filings / Crossject SA
Crossject SA: Form D filing
Crossject SA, a pharmaceuticals company in Dijon, France, filed a Form D with the SEC in 2026. The latest, on June 5, 2026, reports an offering of $10.3 million with nothing sold yet to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6 RUE PAULINE KERGOMARD, Dijon, France, 21000
- Phone
- 33 (0)3 80 54 98 50
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- France
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2136893
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | New notice | $10,259,936 | $0 | $10,259,936 | 2 | May 27, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Patrick Alexandre | Executive Officer, Director | |
| Isabelle Liebschutz | Executive Officer, Director | |
| Didier Morin | Executive Officer | |
| Lionel Seltz | Executive Officer | |
| Olivier Lacombe | Executive Officer | |
| Tony Tipton | Executive Officer |
Every Form D from the week of Jun 1, 2026 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Crossject SA reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.